Dr Abhishek Verma

Dr Abhishek Verma

Conjoint Fellow

School of Medicine and Public Health

Career Summary

Biography

Dr Abhishek Verma is an Australian trained doctor, holding both General and Specialist registration with AHPRA.

Abhi completed an undergraduate medicine degree at the University of New South Wales in 2008, where he won the RANZCO Ophthalmology Medal, the Australian Cancer Council Medical Student Scholarship, the NSW Rural Doctors Network Bush Bursary, the Advancing Australia Fairly Prize and an MDA Medical Elective Travel Bursary. Abhi then completed a Master of Surgery from the University of Sydney in 2014 and achieved his Fellowship of the RACGP in 2016.

Abhi was first appointed a Conjoint Academic at the School of Medicine & Public Health at The University of Newcastle at the age of 25. 

Abhi has interests in teaching medical students, providing clinical tutorials as well as formal teaching in basic sciences. Abhi also provides teaching for doctors training in general practice/family medicine, and is a current examiner for the RACGP Fellowship Exam. Abhi has previously served on the Academic Council of Assessment for the RACGP as the New Fellow Representative.

 

Keywords

  • General Practice
  • Medical Education
  • Medical Regulation

Languages

  • English (Mother)

Fields of Research

Code Description Percentage
110399 Clinical Sciences not elsewhere classified 100
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
2011 Verma A, Roach P, 'Interpreting Arterial Blood Gases', Abnormal Laboratory Results, McGraw-Hill Press, Sydney 78-89 (2011)

Journal article (7 outputs)

Year Citation Altmetrics Link
2015 Verma A, Verma A, 'A Novel Review of the Evidence Linking Myopia and High Intelligence', Journal of Ophthalmology, (2015)
2014 Verma AK, Bourke B, 'Millipede burn masquerading as trash foot in a paediatric patient', ANZ JOURNAL OF SURGERY, 84 388-390 (2014)
DOI 10.1111/ans.12279
Citations Web of Science - 1
2014 Verma AK, Bourke B, 'Millipede burn masquerading as trash foot in a paediatric patient', ANZ Journal of Surgery, 84 388-390 (2014) [C3]
DOI 10.1111/ans.12279
Citations Scopus - 2
2010 Verma AK, 'Dabigatran etexilate: A new thrombin inhibitor', Medical Journal of Australia, 192 407-412 (2010) [C1]
Citations Scopus - 7Web of Science - 6
2009 Verma AK, Brighton TA, 'The direct factor Xa inhibitor rivaroxaban', Medical Journal of Australia, 190 379-383 (2009)

¿ Warfarin and heparin are the traditional mainstay anticoagulant therapies for treating thromboembolic disease. ¿ These drugs, with a documented history of utility, also have inh... [more]

¿ Warfarin and heparin are the traditional mainstay anticoagulant therapies for treating thromboembolic disease. ¿ These drugs, with a documented history of utility, also have inherent difficulties in usage; in particular, the complicated monitoring and numerous drug-drug interactions of warfarin, and the need for parenteral administration of heparins. ¿ New agents have recently emerged that target specific elements of the clotting pathway. Rivaroxaban, which inhibits activated factor X (Xa), is currently in clinical trials and is the most advanced factor Xa inhibitor. ¿ The drug offers once-daily oral dosing, with no need for injections, dose titration, or frequent blood tests to monitor the international normalised ratio. It has a rapid onset of action and, although there is no specific antidote, it has a short plasma elimination half-life (about 5-9 hours). ¿ Evidence from recently published large-scale phase III clinical trials shows rivaroxaban to be superior to enoxaparin for prophylaxis of venous thromboembolism after major orthopaeclic surgery. ¿ Studies have shown rivaroxaban to have a sound safety profile, with an incidence of bleeding similar to enoxaparin in phase III clinical trials. ¿ Few side effects and drug-drug interactions between rivaroxaban and common medications have been found thus far, although some interactions with potent cytochrome P450 3A4 inhibitors have been observed. ¿ It is hoped that rivaroxaban may be used as a first-line anticoagulant for prophylaxis of venous thromboembolic disease in postsurgical patients.

Citations Scopus - 15
2009 Verma AK, 'New agents for orthopaedic thromboprophylaxis: Caution essential, but time will tell', ANZ Journal of Surgery, 79 773-774 (2009)
DOI 10.1111/j.1445-2197.2009.05099.x
Citations Scopus - 1
2007 Verma A, 'Understanding and Managing Cancer Needs Though the Kaleidoscope of Culture', Cancer Forum, 31 165-168 (2007)
Show 4 more journal articles
Edit

Dr Abhishek Verma

Position

Conjoint Fellow
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email abhishek.verma@newcastle.edu.au
Phone (03) 9771 2000
Fax (03) 9771 2001

Office

Location Melbourne, AUS

,
Edit